| Ytd | -87.00% | |
| 1y | -78.04% |
| Open | Prev Close | 3.69 | Low | High | Mkt Cap | 4.65M | |||
| Vol | 0.00 | Avg Vol | 49.29K | EPS | -14.76 | P/E | -0.25 | Forward P/E | -0.42 |
| Beta | 0.76 | Short Ratio | 3.70 | Inst. Own | 42.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.85 | 200-d Avg | 17.54 | 1yr Est | 9.00 |
BCAB News
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up,
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a globa
Initiated a formal process to monetize assets Implemented a restructuring plan to significantly red
Shares of Smith & Wesson Brands Inc (NASDAQ:SWBI) rose sharply in pre-market trading after the c
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a globa
BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a large decrease in short interest in the month o
Shares of BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) have earned an average recommendation of "H
SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage b
BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a significant decline in short interest during th
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report)
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage b
BioAtla, Inc. ( BCAB ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jay
Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will eval
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma,
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage b
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage b
Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release sy
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage b
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpo
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 AM ET Company Part
On Monday, 369 companies set new 52-week lows.
On Monday, 147 stocks hit new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
On Friday, 209 companies set new 52-week lows.
On Thursday, 105 stocks hit new 52-week lows.